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clinical or radiological pneumonitis did not reach statistical 
significance (P<0.05). 
 
 
 
Conclusion: SABR for primary lung cancer performed at the 
Leeds Cancer Centre continues to show excellent local 
control rates, with low toxicity and has comparable overall 5-
year survival rates to other published series. Poorer 
performance status and larger tumour size were associated 
with a negative effect on overall survival. 
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Purpose or Objective: To investigate the prognostic value of 
[(18)F] fluorodeoxyglucose positron emission tomography 
(FDG-PET) uptake before stereotactic ablative radiotherapy 
(SABR) for stage I non-small-cell lung cancer (NSCLC). 
 
Material and Methods: From August 2009 to December 2014, 
80 medically inoperable patients with proven Stage I NSCLC 
or FDG-PET-positive primary lung tumors were analyzed 
retrospectively. SABR consisted of 48-50 Gy delivered in 4 to 
5 fractions, respectively by two or one fraction per week. 
Maximum standardized uptake value (SUV (max)) of the 
treated lesion was assessed before SABR. Patients were 
subsequently followed at regular intervals using computed 
tomography (CT) and FDG-PET scans. Association between 
post-SABR SUV (max, at minimum of 12 weeks after 
treatment) and local control (LC), overall survival (OS) was 
examined. 
 
Results: Median follow-up time was 20 months (range, 9-55 
months). Median lesion size was 20 mm (range, 8-50 mm). 
Due to statistical evaluations around the median range of SUV 
(max), a pre SABR SUV (max) 5.0 was selected as a cut-off to 
analyze LC and OS. The 2-year LC was 61.2% versus 78.7% for 
higher or equal than 5.0 versus lower than 5.0 SUV (max), 
yielding an adjusted sub-hazard ratio (SHR) for high pre SABR 
SUV (max) of 5.3 (95% confidence interval [CI], 1.3-25.5; p = 
0.057). Two-year OS was 80.6% versus 76.6% respectively 
(hazard ratio [HR], 1.4; 95%; p = 0.46). No differences were 
observed between fractionation schedules or different tumor 
volumes. 
 
 
 
Conclusion: FDG uptake (SUV (max) ≥5.0) before SABR 
signifies reduces risk of local failure. These results from 
single institution might stimulate a large accrual from 
multicenter prospective analysis, due to controversial results 
already published. 
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Purpose or Objective: To report our initial experience in 
stereotactic body radiation therapy (SBRT) delivered using 
RapidArc (RA) technique with or without flattening filter 
beam in terms of toxicity and clinical outcomes. 
 
Material and Methods: From September 2013 to September 
2015, 16 consecutive patients with 27 metastatic hepatic 
lesions were treated with SBRT in a TrueBeam unit using RA 
technique. 6 lesions received a Volumetric Modulated Arc 
Therapy (VMAT) treatment using 6Mv RA with flattening filter 
and 21 were treated without flattening filter (flattening filter 
free beam- FFF) with an energy of 10Mv. GTV was defined 
using multi-phase CT scans, PET/CT and/or MRI. The lesions 
were marked with a radiopaque coil to localize them in the 
verification CBCT (ConeBeamCT) that was performed daily. 
ITV (internal target volume) was calculated in gated modality 
with internal coil tracking by 2D imaging. Prescribed doses 
ranged from 30-60Gy in 3-5 fractions to ITV. The dose was 
downscaled in cases of not full achievement of dose 
constraints. 99.5% of the target volume was covered by 100% 
of the prescription dose. Initially, we followed the 
constraints proposed by Timmerman: Three fractions 
constraints for organs at risk were: 700cc of liver free from 
the 17.1Gy isodose, Dmax< 24Gy for stomach and duodenum, 
D5cc< 15Gy for duodenum, Dmax< 30Gy for heart, D1.2cc< 
11Gy and D0.25Gy< 18Gy for spinal cord. Five fractions 
constraints for organs at risk were: 700cc of liver free from 
the 21Gy isodose, Dmax< 32Gy for stomach and duodenum, 
D5cc< 18Gy for duodenum, Dmax< 38Gy for heart, D1.2cc< 
13.5Gy and D0.25Gy< 22.5Gy for spinal cord. Nowadays we 
are following the constraints proposed by the Spanish Society 
of Radiation Oncology: Liver: 700cc of liver free from the 
15Gy isodose, V21<30%, V15<20Gy, Mean dose: <15Gy for 
three fractions and <20Gy for five fractions; D5cc<15Gy for 
duodenum; V30<1cc and V21<5cc for heart; Dmax<18Gy for 
spinal cord. 
 
Results: Mean age of the patients was 59 years and the mean 
following time since the end of SBRT was 9.14 months. ITV 
mean volume was 41.78cc. The most frequent side effect was 
acute asthenia and we identified two cases of asymptomatic 
increase in liver enzymes. No patient experienced acute 
toxicity greater than Grade 2. In relation to the local 
response, we used RECIST and/or PERCIST criteria to 
reevaluate the lesions. We found 15 complete and 1 partial 
responses, 1 progression, 5 stable lesions and 2 pseudo 
progressions. 2 patients (4 lesions) were lost in the long-term 
clinical follow up. No differences between both treatment 
modalities (with or without FF) were found in terms of local 
control or side effects (either acute or chronic). 
 
Conclusion: SBRT for liver targets delivered by means of 
RapidArc resulted to be a feasible technique, with few side 
effects and good rates of local response in metastatic liver 
targets. 
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Purpose or Objective: To evaluate the efficacy and safety of 
stereotactic radiation therapy (SRT) in the treatment of 
patients with recurrent pancreatic adnocarcinoma at the 
stump or abdominal lymph node after surgery. 
 
Material and Methods: Between October 1 2011 and May1 
2015, patients with recurrent pancreatic adnocarcinoma at 
the stump or abdominal lymph nodes after surgery were 
enrolled and treated with SRT at our hospital. The primary 
end-point was overall survival after SRT (OS). Secondary end-
points were: local control rates (LC), time to symptom 
alleviation, and toxicity using the Common Terminology 
Criteria for Adverse Events (CTCAE v4.0). 
 
Results: Twenty-four patients with 24 lesions (17 abdominal 
lymph nodes and 7 stumps) were treated with SRT. Among 
these patients, five patients were presented with abdominal 
lymph node and synchronous metastases in liver and lung. For 
the entire cohort, the median OS from diagnosis and SRT 
were 28.93 months and 12.20 months, respectively. The 6-
month, 12-month, and 24-month actuarial LC rates were 95.2 
%, 83.8% and 62.1% respectively. Symptom alleviation was 
observed in 11 of 14 patients reported symptoms (78.6%) with 
a median of 8 days (range, 1-14 days) after SRT. Nine 
patients (37.5%) experienced CTCAE v4.0 Grade 1 to 2 acute 
toxicities; one patient experienced grade 3 acute toxicity due 
to thrombocytopenia. 
 
Conclusion: SRT is a safe and efficacious treatment modality 
for patients with recurrent pancreatic adnocarcinoma at the 
stump or abdominal lymph nodes after surgery. Further 
studies are needed before SRT can be recommended 
routinely. 
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Purpose or Objective: Based on the results of the 
intergroup-0123/RTOG 94-05 trial that demonstrated no 
benefit of dose escalation over 50.4 Gy in definitive 
chemoradiotherapy (CRT) for esophageal carcinoma, 50.4 Gy 
appears to be accepted as a standard dose. Radiobiologically, 
however, higher radiation doses, if safely delivered, could 
lead to better local control. We have used combination of 
standard FP (5-fluorouracil [5-FU] and cisplatin) 
chemotherapy and radiation with doses ≥60 Gy in the 
treatment of non-metastatic esophageal cancer. We report 
clinical outcome of the treatment protocol. 
 
Material and Methods: Between 2002 and 2014, 86 patients 
with stage I-III or IV (M1 LYM) esophageal cancer were 
treated with CRT. Median age of the patients was 68 years 
(range: 46 to 84); 76 were men and 10 were women. 
Histology was squamous cell carcinoma in 98%. Patients were 
divided into 4 groups according to the stage and operability; 
Group 1: stage I patients (n = 10); Group 2: stage II-III 
operable patients (n = 20); Group 3: stage II-III (non-T4) 
inoperable patients (n = 21); and Group 4: stage III-IV (T4/M1 
LYM) patients (n = 35). Chemotherapy protocols were either 
cisplatin (70 mg/m2) plus 5-FU (700 mg/m2 x 4 days) 
administered every 4 weeks or low-dose daily cisplatin (4 
mg/m2) and 5-FU (200 mg/m2). Radiation was given by 10-
MV X rays with a daily fraction of 1.8-2 Gy. Treatment 
volume included primary tumor plus regional lymph nodes. A 
total dose between 60 and 70 Gy was chosen depending on 
the treatment volume. Median radiation dose was 64 Gy 
(range: 50-70 Gy; 5 patients could not complete planned 
treatment). Failure was confirmed by pathology or findings of 
progressive disease on serial endoscopy and/or imaging 
studies. Overall survival (OS) and locoregional control (LC) 
rates were calculated by the Kaplan-Meier method. Toxicities 
were evaluated by the Common Terminology Criteria for 
Adverse Events version 4.0. 
 
Results: For all 86 patients, the 3-year LC and OS rates were 
65% and 29%, respectively; they were 100% and 100%, 
respectively, in Group 1, and 72% and 42%, respectively, in 
Group 2. The 2-year LC and OS were 53% and 14%, 
respectively, in Group 3, and 69% and 25%, respectively, in 
Group 4. Overall response rate was 78% (complete response 
in 31 and partial response in 36). Grade 3 or higher acute 
toxicities, mainly hematological, were observed in 37% of the 
patients and 10% experienced grade 3 or higher late 
toxicities. 
 
Conclusion: CRT with FP and 60-70 Gy of radiation appears to 
be tolerable for patients with esophageal cancer. Although 
outcome of this treatment in inoperable patients is not 
satisfactory, the 3-year LC of 100% for stage I patients and 
76% for stage II-III operable patients appear promising. 
Further investigation is warranted to clarify the optimal 
radiation dose in CRT for esophageal cancer. 
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Purpose or Objective: The objective of this study was to 
investigate the prognostic value of circulating lymphocyte 
level at the beginning of postoperative chemoradiotherapy 
(CRT) in pancreatic adenocarcinoma. 
 
Material and Methods: From 2007 to 2014, 41 patients 
treated with postoperative CRT were analyzed. The median 
dose of radiotherapy was 50.4 Gy (range, 45 – 59.4) and 
chemotherapy was administered after surgery. Absolute 
lymphocyte counts (ALC) was obtained from complete blood 
count tests performed prior to CRT. We analyzed blood 
lymphocyte count as well as clinical parameters to identify 
prognostic factor 
 
Results: With a median follow-up of 16.9 months, 32 patients 
had cancer recurrence and 28 died from the disease. The 
median overall survival (OS) and disease free survival (DFS) 
were 19.7 months and 9.8 months. The median OS of high 
postoperative ALC (>2.074 ×10³/ μL) group was significantly 
longer than that of the lower ALC group (32.0 months versus 
17.0 months, p = 0.007). In multivariate analysis, high 
postoperative ALC was a good prognostic factor for OS. 
(Hazard Ratio = 0.341, CI, 0.149 – 0.778, p = 0.011). High ALC 
at the beginning of postoperative CRT was also a prognostic 
factor for DFS in multivariate analysis (Hazard Ratio = 0.452, 
CI, 0.215 – 0.946, p = 0.035). 
 
 
 
